



AMURA

Press Release

Amura announces single-crystal XRD confirmation for key AMcore™ intermediate in its osteoporosis programme

Cambridge, U.K. – 22nd November 2007

Amura Holdings Limited ("Amura") today announced proof of absolute stereochemistry of a pivotal AMcore™ chiral intermediate used for the synthesis of lead compounds in their osteoporosis programme. The data provides on-going validation towards full large scale preparation of homochiral active pharmaceutical ingredients (API's) ready for IND candidate nomination as potential new treatments for osteoporosis. The single-crystal X-ray structure determination (XRD) was resolved through SAFC Pharma™ at their world-leading Pharmorphix™ solid form research services centre. The results further support development of these compounds towards pre-IND candidate selection and subsequent progression to the clinic.

Amura's lead compounds for their osteoporosis programme are derived from the proprietary AMcore™ scaffold, which provides a turnkey solution for inhibitor design against cysteine peptidases of the CAC1 family. Cysteine peptidases are involved in several diseases and the AMcore™ scaffold provides a powerful platform for discovery of drugs with potential utility against a range of commercially attractive therapeutic targets. The company has programmes selectively targeting cathepsin K, cathepsin S and other members of this family. The cathepsin S programme is anticipated to be at a similar stage as the current cathepsin K programme this time next year.

Amura intends to out-license its cathepsin K inhibitor products for clinical development.

Additional information about Amura is available at the company website: <http://www.amura.co.uk/>

Additional information about Pharmorphix™ is available at: <http://www.safc-pharmorphix.com>

Contact:

Dr Dan Roach
Avlar BioVentures Limited

☎ +44 (0)1954 211515

☎ +44 (0)1954 211516

✉ DRoach@avlar.com